Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2024 | $55.00 | Buy | Guggenheim |
| 2/15/2024 | $44.00 | Outperform | Wolfe Research |
| 10/18/2023 | $18.00 | Buy | Berenberg |
| 10/17/2023 | $18.00 | Buy | Berenberg |
| 10/5/2023 | $19.00 | Outperform | RBC Capital Mkts |
| 6/26/2023 | $14.00 | Outperform | Oppenheimer |
| 1/19/2023 | $17.00 | Overweight | Morgan Stanley |
| 11/21/2022 | $15.00 | Outperform | SVB Leerink |
Guggenheim initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $55.00
Wolfe Research initiated coverage of Alpine Immune Sciences with a rating of Outperform and set a new price target of $44.00
Berenberg initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $18.00
SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)
SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)
SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. "I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a proven track record of success in building both public and private biopharma companies. As Attovia looks toward our next stage of growth and drives our mission of bringing forward first-in-c
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024. First Quarter 2024 Financial Results Cash Position and Runway: As of March
-- Povetacicept administered subcutaneously once every four weeks continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 weeks, associated with remission, resolution of hematuria, and stable renal function (eGFR) -- -- Company reports successful end of phase 2 meeting with FDA, supporting advancement to a registrational, placebo-controlled phase 3 study of povetacicept in IgA nephropathy, targeted in 2H 2024 -- -- Company will host an investor call and webcast today at 5:15 pm ET -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and
15-12G - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023. He succeeds Andrew Sandler, M.D., who will transition responsibilities to Dr. Dummer through the remainder of the year. "Wolfgang is a highly accomplished drug developer with deep expertise in rare disease, immunology, and immunotherapy. His experience working across all phases of clinical development through regulatory approval will be important as we continue to advance our pipeline of new therapie
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of M. Christina Yi to Chief Technology Officer effective August 21, 2023. Ms. Yi has more than 25 years of biopharmaceuticals leadership experience, including manufacturing, quality, and supply chain. She succeeds Wayne Gombotz, Ph.D., who will retire in August. "Christina is an accomplished industry leader and will be a key addition to our executive team as we prepare for a broad development plan for povetacicept. Her expertise and leadership will be important to Alpine as we contin
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he
During the last three months, 11 analysts shared their evaluations of Alpine Immune Sciences (NASDAQ:ALPN), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 4 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 3 3 3 0 0 3M Ago 0 1 0 0 0 Analysts have recently evaluated Alpine Immune Sciences and provided 12-month price targets. The average target is $54.0, accompanied by a high estimate of $65.00 and a low estimate of $41.00. Surpassing the pre
Wedbush analyst Robert Driscoll reiterates Alpine Immune Sciences (NASDAQ:ALPN) with a Neutral and maintains $65 price target.
Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.41) by 31.71 percent. This is unchanged from the same period last year. The company reported quarterly sales of $7.03 million which beat the analyst consensus estimate of $3.52 million by 99.77 percent. This is a 25.09 percent decrease over sales of $9.39 million the same period last year.
- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine's lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway - - Alpine's protein engineering and immunotherapy expertise augments Vertex's toolbox and capabilities - - Vertex to host investor call today, April 10, at 4:30 pm ET - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a biotechnology com
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Conference Call and Webcast Information The link to the webcast will be available in the investor relations section of the Company's website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days
-- Low-dose povetacicept (80 mg administered once every four weeks) was well tolerated during subcutaneous administration and reduced UPCR by greater than 50% in IgA nephropathy -- -- Higher dose povetacicept (240 mg) administered once every four weeks currently being explored -- -- Based on this data Alpine will now seek to begin a pivotal phase 3 IgAN study in the second half of 2024 -- -- Company to host virtual investor call and webcast today at 4:30 pm ET with James Tumlin, M.D. and Jonathan Barratt, Ph.D., FRCP -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammator